TipRanks
Solid Biosciences (SLDB)
NASDAQ:SLDB
US Market
SLDB
Solid Biosciences
RESEARCH TOOLSreports
Want to see SLDB full AI Analyst Report?

Solid Biosciences (SLDB) Stock Forecast & Price Target

1,595 Followers
See the Price Targets and Ratings of:

SLDB Analyst Ratings

Strong Buy
10Ratings
Strong Buy
10 Buy
0 Hold
0 Sell
Based on 10 analysts giving stock ratings to
Solid
Biosciences
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

SLDB Stock 12 Month Forecast

Average Price Target

$19.00
▲(92.11% Upside)
Based on 10 Wall Street analysts offering 12 month price targets for Solid Biosciences in the last 3 months. The average price target is $19.00 with a high forecast of $26.00 and a low forecast of $11.00. The average price target represents a 92.11% change from the last price of $9.89.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","27":"$27","9.75":"$9.75","15.5":"$15.5","21.25":"$21.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":26,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$26.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":19,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$19.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$11.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,9.75,15.5,21.25,27],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.98,8.443076923076923,9.906153846153845,11.36923076923077,12.832307692307692,14.295384615384615,15.758461538461539,17.22153846153846,18.684615384615384,20.147692307692306,21.61076923076923,23.07384615384615,24.536923076923078,{"y":26,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.98,7.904615384615385,8.829230769230769,9.753846153846155,10.678461538461539,11.603076923076923,12.527692307692309,13.452307692307693,14.376923076923077,15.301538461538462,16.226153846153846,17.15076923076923,18.075384615384614,{"y":19,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.98,7.28923076923077,7.598461538461539,7.907692307692308,8.216923076923077,8.526153846153846,8.835384615384616,9.144615384615385,9.453846153846154,9.763076923076923,10.072307692307692,10.381538461538462,10.69076923076923,{"y":11,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.87,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.39,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.21,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.64,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.43,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.2,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.38,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.13,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.19,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.2,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.06,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.88,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.98,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$26.00Average Price Target$19.00Lowest Price Target$11.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Piper Sandler Analyst forecast on SLDB
Biren Amin
Piper Sandler
Piper Sandler
$18
Buy
82.00%
Upside
Reiterated
09/30/26
Analysts Offer Insights on Healthcare Companies: Tectonic Therapeutic (NASDAQ: TECX) and Solid Biosciences (NASDAQ: SLDB)
Leerink Partners Analyst forecast on SLDB
Joseph Schwartz
Leerink Partners
Leerink Partners
$20
Buy
102.22%
Upside
Reiterated
09/16/26
Solid Biosciences: Buy Rating Reiterated With Unchanged $20 Price Target on Clinical and Regulatory Upside Potential
RBC Capital Analyst forecast on SLDB
Luca Issi
RBC Capital
RBC Capital
$18
Buy
82.00%
Upside
Initiated
09/16/26
Solid Biosciences initiated with an Outperform at RBC CapitalSolid Biosciences initiated with an Outperform at RBC Capital
Cantor Fitzgerald Analyst forecast on SLDB
Kristen Kluska
Cantor Fitzgerald
Cantor Fitzgerald
$26
Buy
162.89%
Upside
Reiterated
09/15/26
Cantor Fitzgerald Sticks to Its Buy Rating for Solid Biosciences (SLDB)
H.C. Wainwright Analyst forecast on SLDB
Arthur He CFA
H.C. Wainwright
H.C. Wainwright
$25
Buy
152.78%
Upside
Reiterated
09/14/26
Analysts' Top Healthcare Picks: Pharming Group (PHAR), Solid Biosciences (SLDB)
Citi Analyst forecast on SLDB
Yigal Nochomovitz
Citi
Citi
$14
Buy
41.56%
Upside
Reiterated
09/10/26
Solid Biosciences (SLDB) Gets a Buy from Citi
Truist Financial Analyst forecast on SLDB
Danielle Brill
Truist Financial
Truist Financial
$16→$20
Buy
102.22%
Upside
Initiated
08/21/26
Solid Biosciences assumed with a Buy at TruistSolid Biosciences assumed with a Buy at Truist
J.P. Morgan Analyst forecast on SLDB
Anupam Rama
J.P. Morgan
J.P. Morgan
$11
Buy
11.22%
Upside
Reiterated
08/11/26
Analysts Offer Insights on Healthcare Companies: Clinigence Holdings (NASDAQ: NUTX), Vera Therapeutics (NASDAQ: VERA) and Solid Biosciences (NASDAQ: SLDB)
Needham Analyst forecast on SLDB
Gil Blum
Needham
Needham
$19
Buy
92.11%
Upside
Reiterated
08/07/26
Analysts Offer Insights on Healthcare Companies: CVRx (NASDAQ: CVRX) and Solid Biosciences (NASDAQ: SLDB)
William Blair Analyst forecast on SLDB
Sami Corwin
William Blair
William Blair
―
Buy
―
Reiterated
08/06/26
Analysts Offer Insights on Healthcare Companies: Xenon (NASDAQ: XENE) and Solid Biosciences (NASDAQ: SLDB)
Wedbush Analyst forecast on SLDB
Laura Chico
Wedbush
Wedbush
$16
Buy
61.78%
Upside
Reiterated
05/18/26
Wedbush Reaffirms Their Buy Rating on Solid Biosciences (SLDB)
Chardan Capital Analyst forecast on SLDB
Geulah Livshits
Chardan Capital
Chardan Capital
$15
Buy
51.67%
Upside
Reiterated
05/13/26
Chardan Capital Sticks to Its Buy Rating for Solid Biosciences (SLDB)
Guggenheim Analyst forecast on SLDB
Debjit Chattopadhyay
Guggenheim
Guggenheim
$26
Buy
162.89%
Upside
Initiated
03/20/26
Solid Biosciences initiated with a Buy at GuggenheimSolid Biosciences initiated with a Buy at Guggenheim
Barclays Analyst forecast on SLDB
Gena Wang
Barclays
Barclays
$10→$9
Buy
-9.00%
Downside
Reiterated
11/03/25
Barclays Sticks to Its Buy Rating for Solid Biosciences (SLDB)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Piper Sandler Analyst forecast on SLDB
Biren Amin
Piper Sandler
Piper Sandler
$18
Buy
82.00%
Upside
Reiterated
09/30/26
Analysts Offer Insights on Healthcare Companies: Tectonic Therapeutic (NASDAQ: TECX) and Solid Biosciences (NASDAQ: SLDB)
Leerink Partners Analyst forecast on SLDB
Joseph Schwartz
Leerink Partners
Leerink Partners
$20
Buy
102.22%
Upside
Reiterated
09/16/26
Solid Biosciences: Buy Rating Reiterated With Unchanged $20 Price Target on Clinical and Regulatory Upside Potential
RBC Capital Analyst forecast on SLDB
Luca Issi
RBC Capital
RBC Capital
$18
Buy
82.00%
Upside
Initiated
09/16/26
Solid Biosciences initiated with an Outperform at RBC CapitalSolid Biosciences initiated with an Outperform at RBC Capital
Cantor Fitzgerald Analyst forecast on SLDB
Kristen Kluska
Cantor Fitzgerald
Cantor Fitzgerald
$26
Buy
162.89%
Upside
Reiterated
09/15/26
Cantor Fitzgerald Sticks to Its Buy Rating for Solid Biosciences (SLDB)
H.C. Wainwright Analyst forecast on SLDB
Arthur He CFA
H.C. Wainwright
H.C. Wainwright
$25
Buy
152.78%
Upside
Reiterated
09/14/26
Analysts' Top Healthcare Picks: Pharming Group (PHAR), Solid Biosciences (SLDB)
Citi Analyst forecast on SLDB
Yigal Nochomovitz
Citi
Citi
$14
Buy
41.56%
Upside
Reiterated
09/10/26
Solid Biosciences (SLDB) Gets a Buy from Citi
Truist Financial Analyst forecast on SLDB
Danielle Brill
Truist Financial
Truist Financial
$16→$20
Buy
102.22%
Upside
Initiated
08/21/26
Solid Biosciences assumed with a Buy at TruistSolid Biosciences assumed with a Buy at Truist
J.P. Morgan Analyst forecast on SLDB
Anupam Rama
J.P. Morgan
J.P. Morgan
$11
Buy
11.22%
Upside
Reiterated
08/11/26
Analysts Offer Insights on Healthcare Companies: Clinigence Holdings (NASDAQ: NUTX), Vera Therapeutics (NASDAQ: VERA) and Solid Biosciences (NASDAQ: SLDB)
Needham Analyst forecast on SLDB
Gil Blum
Needham
Needham
$19
Buy
92.11%
Upside
Reiterated
08/07/26
Analysts Offer Insights on Healthcare Companies: CVRx (NASDAQ: CVRX) and Solid Biosciences (NASDAQ: SLDB)
William Blair Analyst forecast on SLDB
Sami Corwin
William Blair
William Blair
―
Buy
―
Reiterated
08/06/26
Analysts Offer Insights on Healthcare Companies: Xenon (NASDAQ: XENE) and Solid Biosciences (NASDAQ: SLDB)
Wedbush Analyst forecast on SLDB
Laura Chico
Wedbush
Wedbush
$16
Buy
61.78%
Upside
Reiterated
05/18/26
Wedbush Reaffirms Their Buy Rating on Solid Biosciences (SLDB)
Chardan Capital Analyst forecast on SLDB
Geulah Livshits
Chardan Capital
Chardan Capital
$15
Buy
51.67%
Upside
Reiterated
05/13/26
Chardan Capital Sticks to Its Buy Rating for Solid Biosciences (SLDB)
Guggenheim Analyst forecast on SLDB
Debjit Chattopadhyay
Guggenheim
Guggenheim
$26
Buy
162.89%
Upside
Initiated
03/20/26
Solid Biosciences initiated with a Buy at GuggenheimSolid Biosciences initiated with a Buy at Guggenheim
Barclays Analyst forecast on SLDB
Gena Wang
Barclays
Barclays
$10→$9
Buy
-9.00%
Downside
Reiterated
11/03/25
Barclays Sticks to Its Buy Rating for Solid Biosciences (SLDB)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
KURAKura Oncology
DNLIDenali Therapeutics
OVIDOvid Therapeutics
HITIHigh Tide
AXGNAxoGen
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Solid Biosciences

3 Months
Sami CorwinWilliam Blair
Success Rate
8/15 ratings generated profit
53%
Average Return
+4.60%
Copying Sami Corwin's trades and holding each position for 3 Months would result in 53.33% of your transactions generating a profit, with an average return of +4.60% per trade.
1 Year
Sami CorwinWilliam Blair
Success Rate
12/15 ratings generated profit
80%
Average Return
+33.42%
Copying Sami Corwin's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +33.42% per trade.
2 Years
Joseph SchwartzLeerink Partners
Success Rate
13/14 ratings generated profit
93%
Average Return
+31.64%
Copying Joseph Schwartz's trades and holding each position for 2 Years would result in 92.86% of your transactions generating a profit, with an average return of +31.64% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

SLDB Analyst Recommendation Trends

Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
12
11
8
12
11
Buy
2
2
2
2
2
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
14
13
10
14
13
In the current month, SLDB has received 13 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. SLDB average Analyst price target in the past 3 months is 19.00.
Each month's total comprises the sum of three months' worth of ratings.

SLDB Financial Forecast

SLDB Earnings Forecast

Next quarter’s earnings estimate for SLDB is -$0.41 with a range of -$0.53 to -$0.32. The previous quarter’s EPS was -$0.38. SLDB beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year SLDB has Performed in-line its overall industry.
Next quarter’s earnings estimate for SLDB is -$0.41 with a range of -$0.53 to -$0.32. The previous quarter’s EPS was -$0.38. SLDB beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year SLDB has Performed in-line its overall industry.

SLDB Sales Forecast

Next quarter’s sales forecast for SLDB is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. SLDB beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year SLDB has Performed in-line its overall industry.
Next quarter’s sales forecast for SLDB is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. SLDB beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year SLDB has Performed in-line its overall industry.

SLDB Stock Forecast FAQ

What is SLDB’s average 12-month price target, according to analysts?
Based on analyst ratings, Solid Biosciences’s 12-month average price target is 19.00.
    What is SLDB’s upside potential, based on the analysts’ average price target?
    Solid Biosciences has 92.11% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is SLDB a Buy, Sell or Hold?
          Solid Biosciences has a consensus rating of Strong Buy which is based on 10 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Solid Biosciences’s price target?
            The average price target for Solid Biosciences is 19.00. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $26.00 ,the lowest forecast is $11.00. The average price target represents 92.11% Increase from the current price of $9.89.
              What do analysts say about Solid Biosciences?
              Solid Biosciences’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.
                How can I buy shares of SLDB?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.